TL;DR: Bramante Biologics manufactures pharmaceutical drugs faster than current methods and in the USA. They are building microfactories that can handle the upcoming wave of AI-designed drugs and safeguard against biothreats.
The team loves biomanufacturing. Together, they built Protein Evolution, an industrial biotech company that turned plastic waste into new textile fibers. Scott is ex-McKinsey and a Yale mathematician (he loves a good cost model almost as much as he loves America). Mike earned his PhD in Bioengineering from Penn after completing Penn’s M&T program in undergrad (he builds DNA, software, and bioreactors).
The Problem
America is at risk of ceding leadership in advanced biomanufacturing to China.
Drug manufacturing is moving to China; 79% of US biotech and pharma companies already have at least one contract with a Chinese firm, primarily because they are faster.
China is investing billions in biotech; one third of new compounds licensed by US pharma are now discovered and manufactured in China, up from almost none five years ago.
Over-reliance on foreign biomanufacturing is a national-security risk; agile, on-shore manufacturing is critical to protect their nation against future biothreats.
A contract development and manufacturing organization (CDMO) for advanced drugs, rebuilt from the ground up to address the future of America’s biomanufacturing needs.
Faster biomanufacturing; Their platform leverages advanced methods to accelerate production timelines and de-risk scale-up.
Modular container factories; Their form factor is a standard shipping container that can be brought up to operation in roughly two weeks and shipped where it is needed.
Supply-chain independence; by vertically integrating and manufacturing critical equipment in-house, they secure production against global disruptions.
Why It Matters
Drugs can be developed faster; shorter production cycles move life-saving drugs from the lab to the clinic up to a year sooner.
More drugs can be developed; they will be able to manufacture the thousands of low-volume, personalized biologics that will be designed by AI.
Strengthening US autonomy; rapid-deploy, U.S.-based capacity protects the nation from supply shocks, geopolitical turbulence, and potential bioweapons.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
.png)
